As shown in patients with NSCLC, in colorectal or pancreatic cancer patients treated with anti-EGFR targeted treatments reviewed in [83], there is a subgroup of patients that is particularly benefited from such treatments, that is, those who develop the typical acne-like or maculopapular rash [57]. Here, EGFR is linked to non-small cell lung carcinoma.